Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$131.25
pos +0.00
+0.00%
Today's Range: 130.77 - 133.00 | CELG Avg Daily Volume: 4,629,800
Last Update: 07/31/15 - 3:59 PM EDT
Volume: 0
YTD Performance: 17.33%
Open: $0.00
Previous Close: $131.88
52 Week Range: $83.16 - $140.72
Oustanding Shares: 790,540,158
Market Cap: 104,256,436,037
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 12 12 13
Moderate Buy 1 1 1 1
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.47 1.44 1.44 1.41
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 49.95
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
49.95 50.00 25.63
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
21.46% 50.60% 283.44%
GROWTH 12 Mo 3 Yr CAGR
Revenue 18.10 0.58 0.16
Net Income 37.90 0.52 0.15
EPS 42.00 0.72 0.20
Earnings for CELG:
EBITDA 2.94B
Revenue 7.67B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $1.01 $1.16 $4.22 $5.53
Number of Analysts 1 1 1 1
High Estimate $1.01 $1.16 $4.28 $5.53
Low Estimate $1.01 $1.16 $4.15 $5.53
Prior Year $0.88 $0.91 $3.36 $4.22
Growth Rate (Year over Year) 14.77% 27.47% 25.45% 31.20%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

David Katz

 | Jul 30, 2015 | 11:00 AM EDT

Drugmaker has one of the best showings of earnings season.

By

David Katz

 | Jul 30, 2015 | 8:30 AM EDT

Drugmaker has one of the best showings of earnings season.

By

Jim Cramer

 | Jul 24, 2015 | 12:32 PM EDT

TheStreet's Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

By

Jim Cramer

 | Jul 24, 2015 | 11:24 AM EDT

Biogen's weak numbers leave biotechs ailing.

By

Bret Jensen

 | Jul 20, 2015 | 11:30 AM EDT

How Netflix, Tesla and Amazon are helping this market grind higher.

By

Jim Cramer

 | Jul 20, 2015 | 11:27 AM EDT

The fearsome foursome have been reborn.

By

Ed Ponsi

 | Jul 17, 2015 | 2:00 PM EDT

Let's review.

By

Jim Cramer

 | Jul 16, 2015 | 2:51 PM EDT

They should learn to trust techs, financials.

By

Jim Cramer

 | Jul 16, 2015 | 1:11 PM EDT

It's like buying at the top -- and I don't like buying at the top.

By

Jim Cramer

 | Jul 16, 2015 | 11:42 AM EDT

Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.

$51 billion - How much Uber is valued at in its last financing round. The unicorns keep g...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.